<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1402">
  <stage>Registered</stage>
  <submitdate>11/12/2006</submitdate>
  <approvaldate>11/12/2006</approvaldate>
  <nctid>NCT00410306</nctid>
  <trial_identification>
    <studytitle>Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice</studytitle>
    <scientifictitle>International, Multi-center Post Authorization Surveillance Study on the Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido)</scientifictitle>
    <utrn />
    <trialacronym>IPASS Nebido</trialacronym>
    <secondaryid>2005/00888</secondaryid>
    <secondaryid>14203</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Male</healthcondition>
    <healthcondition>Hypogonadism</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Testosterone Undecanoate (Nebido, BAY86-5037)

Group 1 - 


Treatment: drugs: Testosterone Undecanoate (Nebido, BAY86-5037)
Patients from routine practice

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adverse events, adverse drug reactions, patient reported tolerability</outcome>
      <timepoint>during 4 injection intervals</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in laboratory values (total testosterone, estradiol, SHGB, FSH, LH) from baseline to end of observation</outcome>
      <timepoint>after 4 injection intervals</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in subjective assessment of the patient (overall sexual desire/libido, vigor/vitality, mood, ability to concentrate) from baseline to end of observation</outcome>
      <timepoint>after 4 injection intervals</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in intensity of symptoms or disorders associated with low testosterone (hot flushes or excessive sweating, sleep disturbances, decreased physical strength and erectile dysfunction) from baseline to end of observation</outcome>
      <timepoint>after 4 injection intervals</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient reported outcome at end of observation (satisfaction with current androgen therapy, comparison to previous androgen therapy, if applicable)</outcome>
      <timepoint>after 4 injection intervals</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment continuation rate</outcome>
      <timepoint>after 4 injection intervals</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vital signs and anthropometric measurements (Blood pressure, heart rate, weight and waist circumference)</outcome>
      <timepoint>during 4 injection intervals</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Laboratory values (PSA, hemoglobin, hematocrit, HbA1C, T-chol, HDL-chol, LDL-chol, triglycerides)</outcome>
      <timepoint>during 4 injection intervals</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Digital rectal examination</outcome>
      <timepoint>during 4 injection intervals</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male hypogonadal patients eligible for long-term testosterone therapy who have newly
             been prescribed Nebido® in accordance with the terms of the marketing authorization</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients presenting with contraindications as stated in the product information</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1493</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Many Locations</hospital>
    <postcode> - Many Locations</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Indonesia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Jordan</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Kazakhstan</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lebanon</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Macedonia, The Former Yugoslav Republic of</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malta</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Moldova, Republic of</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovenia</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Many Locations</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bayer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an observational study with a drug called Nebido, a new testosterone replacement
      therapy, which is available for the treatment of male hypogonadism. The benefit and safety of
      Nebido have already been thoroughly evaluated through well controlled clinical trials. The
      main purpose of this observational study is to confirm the established safety profile of
      Nebido in daily clinical practice.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00410306</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bayer Study Director</name>
      <address>Bayer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>